Quantify the share of a sourcing lane handled by traders vs direct manufacturers. Visibility into who actually moves the goods on the destination shelf.
The 2024 median lane runs at 6% trader share: most observable trade is manufacturer-direct. The mean sits higher at 14.5% because a handful of trader-heavy lanes pull the right tail. The IN to AG lane runs at 72.4% trader share (n=27.6% manufacturer); the IN to US lane runs at 1.2% (98.8% direct). The tail is where intermediation risk concentrates.
Type origin and destination. The AI agent pulls every named exporter on the lane and classifies them as manufacturer, trader, or unclassified.
Trader share, manufacturer share, distinct-manufacturer count, and unclassified residual. Time series on quarterly granularity.
Citation-anchored brief with the split, the direct-manufacturer cohort, and a chip showing trader-share trajectory quarter on quarter.
A trader-led lane carries an intermediation margin the buyer pays without seeing. The split is the first signal that a direct relationship will move the price.
Once trader share is known, the named direct manufacturers on the lane are the dual-source candidates. The split surfaces them automatically.
Trader share that rises quarter on quarter signals that manufacturers are exiting the direct channel. Catching the trend early is the leverage.
Counterparty identities are aggregated at the threshold required by the trade-data disclaimer. Lane-level shares, never named buyer-to-seller transactions.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Eighteen high-volume IN-origin lanes · trader share, 2024.
Trader vs manufacturer share is the intermediation signal on any sourcing lane. PharmaDB classifies every named exporter as manufacturer, trader, or unclassified, and reports the split per lane per year. The view rests on lane_trader_shares joined to global_companies. Refresh cadence is weekly.
PharmaDB classifies named exporter entities using a combination of regulatory registrations (Type II DMF holders, plant accreditations, plant catalog match) and trade pattern signals (broad-molecule single-shipment patterns vs concentrated-molecule recurring patterns). The classification carries a confidence flag on every row.
Small destination markets often consolidate imports through trading intermediaries based in regional hubs. The aggregate trader share on these lanes routinely runs above 60 percent; direct manufacturer relationships are rarer because the volume per buyer is small.
Identify the direct manufacturer cohort on the lane (the residual after the trader share), engage them on their own home lane (typically a larger volume corridor where they ship direct), then qualify them on the buyer's lane. The trader margin moves to the manufacturer or to the buyer.
Lane-level aggregates only. PharmaDB never surfaces named buyer-to-seller transactions in product views; the trade-data disclaimer is honoured at the query layer.
Weekly. Trade aggregates refresh weekly; the classification reruns on every refresh. The catalog row carries an as-of timestamp on every result page.
Yes. The same methodology applies to FDF (finished dosage) lanes. Trader share on FDF lanes is typically higher than on API lanes because finished products are more often routed through distributor or trader intermediaries.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.